about
The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomyRisk assessment for prostate cancer metastasis and mortality at the time of diagnosisActive surveillance for prostate cancer: progress and promiseProstate-cancer screeningSerum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes?Use of social media in urology: data from the American Urological Association (AUA).Contemporary trends in imaging test utilization for prostate cancer staging: data from the cancer of the prostate strategic urologic research endeavor.How potent is potent? Evaluation of sexual function and bother in men who report potency after treatment for prostate cancer: data from CaPSURE.Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE).Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE.The impact of obesity on health related quality of life before and after radical prostatectomy (data from CaPSURE).Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE.Differences in clinical characteristics and disease-free survival for Latino, African American, and non-Latino white men with localized prostate cancer: data from CaPSURE.Decreasing size at diagnosis of stage 1 renal cell carcinoma: analysis from the National Cancer Data Base, 1993 to 2004.Renal cell cancer stage migration: analysis of the National Cancer Data Base.Sociodemographic and clinical risk characteristics of patients with prostate cancer within the Veterans Affairs health care system: data from CaPSURE.Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE.In vivo tumor grading of prostate cancer using quantitative 111In-capromab pendetide SPECT/CT.The independent value of tumour volume in a contemporary cohort of men treated with radical prostatectomy for clinically localized disease.Time trends and local variation in primary treatment of localized prostate cancerUrologist density and county-level urologic cancer mortalityPrognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomyCigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database.High-risk prostate cancer in the United States, 1990-2007Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.Contemporary trends in low risk prostate cancer: risk assessment and treatmentNational practice patterns and time trends in androgen ablation for localized prostate cancer.The changing face of low-risk prostate cancer: trends in clinical presentation and primary management.Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy.Outcomes of active surveillance for men with intermediate-risk prostate cancer.Impact of age at diagnosis on prostate cancer treatment and survivalThe example of CaPSURE: lessons learned from a national disease registryThe CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy.Androgen deprivation therapy and cardiovascular risk.The evolving role of androgen deprivation therapy in the management of prostate cancer.The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry.Patterns of practice in the United States: insights from CaPSURE on prostate cancer management.Among potent men post radical prostatectomy, does the need for phosphodiesterase inhibitors have an impact on sexual bother scores?Prostate cancer 2004: insights from national disease registries.Percutaneous neuromodulation.
P50
Q24596735-8CA04409-5764-4D83-B26C-B376D73179D9Q24645292-801067AC-C67C-4075-AF7B-F71A3D38FDE9Q28245173-FEBF745D-0348-4665-B505-D8450921F2E0Q28251611-6EABB45B-AB84-4998-9C84-3B30295A4DC7Q28301925-7C1AE061-4416-4F0A-A7EB-DC63F3648D57Q30701248-B0C79D13-4F1D-493E-B4C6-8B890FC659F6Q30705475-17B54390-1BB3-480A-9E93-AA2152652C83Q30764893-389AAF89-5A65-42D3-9AA6-DAFED9E005D1Q30883910-E2FD5F6D-D12F-49FE-9B20-107F735F1A4FQ30982763-EAA370A3-BD0B-45C5-9649-7FAF64AA8A91Q30984516-53B573DC-AD48-4B45-9EFE-3F4D4C6A7928Q31018353-5D1FAC78-9C99-4D1D-B52D-3B6108F6462CQ31029052-9720AD90-EEBC-434A-98B9-C823BB9CC8F5Q31153111-B7EF7CF9-826B-4725-B031-CFA040CA2018Q31156006-782E6A15-527E-4B23-A934-1250B85B855EQ33188118-012727B1-9B03-408D-BBD3-4EE3EED8CF96Q33212708-F4DE6C1C-7D41-4A9A-8D39-0F4DF018A8C3Q33649303-A67493B1-DD83-4204-A410-495BC966A76AQ33651064-C8A9C8DC-F98A-4841-8CD2-29CCFB5D4DA9Q33710948-0BAB6F90-8BAC-4D0F-9842-D7361C8F57D5Q33897635-3FDB590E-530F-4CF7-8A30-CCBC233DCF18Q34091402-83EEEBE8-40B9-43FB-9668-8CF71F243958Q34108249-17F94909-24E6-44CD-B73F-BEA192DB0712Q34168382-6362FD4D-909F-4E49-8C20-AEEA57AED458Q34288796-A65D09BD-555E-47A8-AE5C-F53AB92A376BQ34330041-380C18B6-B3BB-4CE6-93B2-2C722260BC3EQ34363769-F579616D-003D-4D35-9D2A-BD578614EBCCQ34380870-B96F6A40-A85C-4E00-BA88-EE1A8F8AE671Q34573737-1746CA94-FE56-402E-A654-E09426DEC581Q34679207-2D13C6A9-75F6-4405-87D2-E0992BD40898Q34679220-1964F79D-6513-4081-BC7B-46086475B6AFQ34996369-5F64893F-89DC-4792-8B7F-5C09B0BF691AQ35207309-B686D52D-C455-4E58-AF8E-A6C36DB870ABQ35229730-86CA8668-97D6-4306-A82B-B3F9D46162EEQ35649783-4D034AD9-5710-4DB5-ACD9-616E334109E6Q35689357-F0007C13-BB84-4042-83DD-8958FE6A56A7Q35782994-6D4F3B4B-ABC3-4542-B520-2EE506F33E2DQ35785290-15C1BCD9-063D-48F9-9D0E-1EB9F0F1F2ACQ35939418-706F9B2D-06AC-474D-BA79-295E89EB8060Q36033629-7896BF51-46C7-4948-B2E9-BBCC5F5E4CF2
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Matthew R Cooperberg
@ast
Matthew R Cooperberg
@en
Matthew R Cooperberg
@es
Matthew R Cooperberg
@nl
Matthew R Cooperberg
@sl
type
label
Matthew R Cooperberg
@ast
Matthew R Cooperberg
@en
Matthew R Cooperberg
@es
Matthew R Cooperberg
@nl
Matthew R Cooperberg
@sl
prefLabel
Matthew R Cooperberg
@ast
Matthew R Cooperberg
@en
Matthew R Cooperberg
@es
Matthew R Cooperberg
@nl
Matthew R Cooperberg
@sl
P106
P2002
P21
P31
P496
0000-0003-4339-6685